Emerging Therapeutic Strategies for Hearing Loss

IF 3.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Shanying Han, Tian Shen, Weiwei He, Hao Wei, Xiaolong Zhao, Wen Yang, Chuan Bu, Xinghua Tang, Yu Zhao, Jiangang Fan
{"title":"Emerging Therapeutic Strategies for Hearing Loss","authors":"Shanying Han,&nbsp;Tian Shen,&nbsp;Weiwei He,&nbsp;Hao Wei,&nbsp;Xiaolong Zhao,&nbsp;Wen Yang,&nbsp;Chuan Bu,&nbsp;Xinghua Tang,&nbsp;Yu Zhao,&nbsp;Jiangang Fan","doi":"10.1002/adtp.202500127","DOIUrl":null,"url":null,"abstract":"<p>Hearing loss (HL) is a significant global health challenge, affecting billions of people and severely impacting quality of life. While traditional interventions such as hearing aids and cochlear implants mitigate symptoms, they fail to address the underlying causes of HL, especially in cases involving severe damage to hair cells or spiral ganglion neurons. Emerging therapeutic strategies, including biomaterials, nanocarrier drug delivery systems, gene therapy, and extracellular vesicle (EV)-based approaches, have demonstrated significant potential in promoting inner ear regeneration and restoring auditory function. Biomaterials mimic the extracellular matrix to guide inner ear cell regeneration, while nanocarriers and EVs enhance the targeted and sustained delivery of therapeutic agents. Gene therapy offers opportunities to correct genetic mutations, addressing hereditary HL. However, challenges such as the anatomical complexity of the cochlea, the blood-labyrinth barrier, and limited regenerative capacity persist. Future research must focus on scalable, biocompatible, and clinically safe delivery systems to advance the clinical translation of these innovative therapies. This review underscores the potential of integrating these strategies to develop effective and long-lasting treatments for HL.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 7","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202500127","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/adtp.202500127","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Hearing loss (HL) is a significant global health challenge, affecting billions of people and severely impacting quality of life. While traditional interventions such as hearing aids and cochlear implants mitigate symptoms, they fail to address the underlying causes of HL, especially in cases involving severe damage to hair cells or spiral ganglion neurons. Emerging therapeutic strategies, including biomaterials, nanocarrier drug delivery systems, gene therapy, and extracellular vesicle (EV)-based approaches, have demonstrated significant potential in promoting inner ear regeneration and restoring auditory function. Biomaterials mimic the extracellular matrix to guide inner ear cell regeneration, while nanocarriers and EVs enhance the targeted and sustained delivery of therapeutic agents. Gene therapy offers opportunities to correct genetic mutations, addressing hereditary HL. However, challenges such as the anatomical complexity of the cochlea, the blood-labyrinth barrier, and limited regenerative capacity persist. Future research must focus on scalable, biocompatible, and clinically safe delivery systems to advance the clinical translation of these innovative therapies. This review underscores the potential of integrating these strategies to develop effective and long-lasting treatments for HL.

Abstract Image

新兴的听力损失治疗策略
听力损失是一项重大的全球健康挑战,影响着数十亿人,严重影响着生活质量。虽然助听器和人工耳蜗等传统干预措施可以缓解症状,但它们无法解决HL的根本原因,特别是在毛细胞或螺旋神经节神经元严重受损的情况下。新兴的治疗策略,包括生物材料、纳米载体药物递送系统、基因治疗和基于细胞外囊泡(EV)的方法,已经证明了促进内耳再生和恢复听觉功能的巨大潜力。生物材料模拟细胞外基质来引导内耳细胞再生,而纳米载体和ev增强了治疗剂的靶向性和持续性。基因治疗提供了纠正基因突变的机会,解决遗传性HL。然而,耳蜗解剖的复杂性、血迷宫屏障和有限的再生能力等挑战仍然存在。未来的研究必须集中在可扩展、生物相容性和临床安全的给药系统上,以推进这些创新疗法的临床转化。本综述强调了整合这些策略以开发有效和持久治疗HL的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advanced Therapeutics
Advanced Therapeutics Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
7.10
自引率
2.20%
发文量
130
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信